Responses have not been uniform, however [46], and further clinical trial data must be accumulated before defining the role of mTOR inhibition in metastatic or recurrent PEComa-NOS. The gene discussed is MTOR; the disease is neoplasm with perivascular epithelioid cell differentiation.